- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00423280
Effect of 6R-BH4 Treatment in Coronary Artery Disease (OXBIO Study)
A Randomised, Placebo-Controlled Study of Two Doses of Oral 6R-BH4 on Vascular Function in Subjects With Coronary Artery Disease
Study Overview
Detailed Description
Decreased production of nitric oxide (NO) from the endothelium (the layer of cells that forms the lining of all blood vessels) has been shown to contribute to atherosclerosis. NO has multiple beneficial effects on vascular function. Endothelial function can be measured in humans via a number of methods, and endothelial dysfunction has been shown to be a strong adverse predictor of cardiovascular events and mortality.
Tetrahydrobiopterin (BH4) is essential for the production of NO in endothelial cells. 6R-BH4 is a synthetic version of naturally occurring BH4. We aim to investigate the effects of oral 6R-BH4 supplementation on endothelial function in patients with coronary artery disease.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Colin Cunnington, MBChB MRCP
- Phone Number: +44-1865-221866
- Email: colin.cunnington@cardiov.ox.ac.uk
Study Locations
-
-
-
Oxford, United Kingdom, OX3 9DU
- Recruiting
- Department of Cardiovascular Medicine, University of Oxford
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Multi-vessel coronary artery disease scheduled for coronary artery bypass surgery (CABG)
Exclusion Criteria:
- Inability to provide informed consent
- Female subject who is pregnant, lactating or planning pregnancy during course of study
- Prior clinical diagnosis of heart failure requiring diuretic therapy with evidence of severe left ventricular dysfunction
- Recent acute coronary event (<4 weeks)
- Emergency CABG
- Newly diagnosed diabetes mellitus (<1 month)
- Body weight >130kg
- Impaired renal function (creatinine >180umol/l)
- Elevated liver function tests (ALT >50umol/l or AST >2x normal)
- Pacemakers, ICDs or metallic implants not compatible with MRI scanning
- Subjects receiving experimental medications or participating in another study
- Terminally ill subjects
- Known hypersensitivity to 6R-BH4
- Concomitant treatment with methotrexate, levodopa, PDE-3 or PDE-5 inhibitors
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 3
Placebo
|
6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
Other Names:
|
Active Comparator: 1
700mg/day 6R-BH4
|
6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
Other Names:
|
Active Comparator: 2
400mg/day 6R-BH4
|
6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Vascular function using non-invasive magnetic resonance imaging (MRI).
Time Frame: Pre- and post- treatment with 6R-BH4 or placebo
|
Pre- and post- treatment with 6R-BH4 or placebo
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Laboratory measures of vascular function.
Time Frame: At time of CABG surgery
|
At time of CABG surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Keith M Channon, MD FRCP, University of Oxford
Publications and helpful links
General Publications
- Cunnington C, Van Assche T, Shirodaria C, Kylintireas I, Lindsay AC, Lee JM, Antoniades C, Margaritis M, Lee R, Cerrato R, Crabtree MJ, Francis JM, Sayeed R, Ratnatunga C, Pillai R, Choudhury RP, Neubauer S, Channon KM. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation. 2012 Mar 20;125(11):1356-66. doi: 10.1161/CIRCULATIONAHA.111.038919. Epub 2012 Feb 7.
- Cunnington C, Channon KM. Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology. Heart. 2010 Dec;96(23):1872-7. doi: 10.1136/hrt.2009.180430. Epub 2010 Sep 13.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06/Q1604/114
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on 6R-BH4
-
Johns Hopkins UniversityBioMarin PharmaceuticalTerminatedEndothelial Dysfunction | Isolated Systolic HypertensionUnited States
-
Merck KGaA, Darmstadt, GermanyCompleted
-
The University of Texas Medical Branch, GalvestonTerminated
-
Emory UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingRenal Insufficiency, ChronicUnited States
-
Astellas Pharma Global Development, Inc.WithdrawnSolid Tumors | Epidermal Growth Factor Receptor (EGFR) Mutations
-
BioMarin PharmaceuticalCompletedPhenylketonuriaUnited States, Canada
-
BioMarin PharmaceuticalCompletedEndothelial DysfunctionUnited States
-
University of NebraskaWithdrawnPeripheral Arterial Disease | Peripheral Artery Disease
-
BioMarin PharmaceuticalCompletedPhenylketonuriaUnited States, Canada
-
University Tunis El ManarCompletedAcute Renal Failure | Pre Eclampsia | Eclampsia, Antepartum | HELLP Syndrome (HELLP), Unspecified Trimester | Abruptio Placentae; Complicating PregnancyTunisia